# Ecallantide (Kalbitor)

> Plasma kallikrein inhibitor for hereditary angioedema.

Source: https://peptides.cafe/peptide/ecallantide
Category: Kallikrein Inhibitor · Immunology
Tag: FDA-Approved · Rare Disease

## Mechanism
60-amino-acid recombinant protein that selectively inhibits plasma kallikrein, reducing bradykinin generation during HAE attacks.

## Research areas
- Hereditary angioedema (acute attacks, ≥12 yrs)

## Common research protocols
- Acute attack: 30 mg SC (three 10 mg injections); may repeat once within 24h.

## Study summaries
- "EDEMA trials" — NEJM (2010): Improved HAE attack resolution vs placebo.

## Considerations
- FDA-approved.
- Boxed warning: anaphylaxis — administer by healthcare professional.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.